Vivli Logo
21 Jan
  • By Greg Freeman
  • Cause in

Global research nonprofit CureDuchenne joins Vivli to share clinical trial data for treating muscular dystrophy

CureDuchenne, the leading global nonprofit focused on finding a cure for Duchenne muscular dystrophy, will contribute patient-level clinical data to the Vivli platform, making it available to other researchers around the world. The data will augment existing studies that are available to request on the Vivli platform, which currently hosts data from over 4,700 trials. […]

READ MORE
Shape Therapeutics Logo
05 Nov
  • By Greg Freeman
  • Cause in

Shape Therapeutics, Inc. raises $35.5M Series A financing, led by NEA and announces the formation of a world-class Scientific Advisory Board, to advance a first-in-class RNA editing gene therapy platform focused on curing genetic diseases.

  The Shape Therapeutics RNAfixTM editing platform uses fully human components and avoids risks associated with in vivo CRISPR-based technologies. The SAB, comprised of industry pioneers in the field of genetics and synthetic biology, includes George Church Ph.D. (Harvard-MIT Health Sciences & Technology), James Collins Ph.D. (Harvard-MIT Health Sciences & Technology), and Don Cleveland Ph.D. […]

READ MORE
12 Oct
  • By Greg Freeman
  • Cause in

Nonprofit CureDuchenne Launches Biobank to Fuel Research for Duchenne Muscular Dystrophy

NEWPORT BEACH, CALIF. – (October 12, 2019) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (Duchenne), announced today it has initiated the development of a biobank for Duchenne.   The CureDuchenne Biobank is dedicated to empowering Duchenne research and the […]

READ MORE
27 Sep
  • By Greg Freeman
  • Cause in

CureDuchenne Invests in Chameleon Biosciences to Support EVADERTM, a Next Generation Adeno Associated Virus Based Gene Therapy Platform Technology

Investment will help advance development of gene therapy technology offering resistance to pre-existing antibodies, enhanced gene delivery and the potential for repeat dosing. NEWPORT BEACH, CALIF. — (September 27, 2019) – CureDuchenne, a global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy (DMD), […]

READ MORE
19 Sep
  • By Greg Freeman
  • Cause in

CureDuchenne Appoints Lianna Orlando, PhD, to the Position of Senior Director of Research

Newport Beach, CA – (September 19, 2019) – CureDuchenne, the leading global nonprofit focused on funding and finding a cure for Duchenne muscular dystrophy, announced today that Lianna Orlando, PhD has joined the team as Senior Director of Research.  In this role, Orlando will help identify and evaluate strategic investments aimed at developing treatments for […]

READ MORE
26 Aug
  • By Greg Freeman
  • Cause in

CureDuchenne Launches Website to Assist Newly Diagnosed Duchenne Families

NEWPORT BEACH, Calif. (August 26, 2019) – Receiving a positive diagnosis for Duchenne muscular dystrophy is devastating for new parents.  Likewise, learning about the rare disease and how to care for a child with Duchenne can be extremely overwhelming.  CureDuchenne hopes to make the beginning stages of a every family’s Duchene journey easier and faster […]

READ MORE
01 Jul
  • By Greg Freeman
  • Cause in

CureDuchenne Cares and Duchenne Family Assistance Program to Provide Support Services to Duchenne Community

Organizations to provide financial support for 50 Duchenne families to travel to Southern California for the CureDuchenne 2019 FUTURES national conference NEWPORT BEACH, Calif. (July 1, 2019) — CureDuchenne, the nonprofit global leader in Duchenne research, patient care and innovation, and the Duchenne Family Assistance Program (DFAP), which is comprised of Duchenne nonprofit advocacy organizations […]

READ MORE
06 Jun
  • By Sha
  • Cause in

Nonprofit CureDuchenne is Encouraged to See Gene Editing for Duchenne Advance Through Vertex’s Acquisition of Exonics Therapeutics

Deal will accelerate drug development for Duchenne muscular dystrophy, a rare disease that affects 300,000 boys and young men worldwide June 06, 2019 07:11 PM Eastern Daylight Time NEWPORT BEACH, Calif.–(BUSINESS WIRE)–CureDuchenne, a nonprofit global leader in research, patient care, and innovation in improving and extending the lives of those living with Duchenne muscular dystrophy […]

READ MORE
01 May
  • By Jessica Yanez-Perez
  • Cause in

Champions to CureDuchenne Magical Night Under the Stars Raises Over $400,000 for Research to Find Cure for Duchenne Muscular Dystrophy

NEWPORT BEACH, CA (April 24, 2019) —  Austin’s finest recently came together for Champions to CureDuchenne, an annual charity event that benefits CureDuchenne, a national nonprofit that funds research to find a cure for Duchenne muscular dystrophy, the most devastating and lethal muscular disease in children. One in every 5,000 boys will be diagnosed with […]

READ MORE